Research programme: polyclonal antibodies - SAB Biotherapeutics

Drug Profile

Research programme: polyclonal antibodies - SAB Biotherapeutics

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SAB Biotherapeutics
  • Class Antineoplastics; Antivirals; Polyclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alphavirus infections; Cancer; Clostridium infections; Dengue; Ebola virus infections; Hantavirus infections; Influenza virus infections; Mycoplasma infections; Viral haemorrhagic fevers; Zika virus infection

Most Recent Events

  • 26 Apr 2017 Preclinical trials in Clostridium infections in USA (unspecified route)
  • 26 Apr 2017 Preclinical trials in Zika virus infection in USA (unspecified route)
  • 07 Sep 2016 SAB Biotherapeutics receives SBIR grant from the National Institutes of Health for the antibody therapeutic targeting influenza viruses
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top